Jessica Madigan and Normand Blais of BIOVECTRA discuss how their company is ideally positioned to add mRNA manufacture to its portfolio, leveraging their new, state-of-the-art facility and manufacturing solutions to support projects from plasmid DNA design and production to fill/finish of mRNA–LNP drug products at all stages from preclinical materials through commercial production.
.svg)
